Compass Therapeutics (NASDAQ:CMPX) Reaches New 1-Year High - Here's What Happened

Key Points

• Compass Therapeutics' stock reached a new 52-week high of $4.09 during mid-day trading, with a high trading volume of over 1.6 million shares.
• Wall Street analysts have varying opinions on the stock, with most ratings being positive; the average target price is $13.10, and one analyst rated it as a Strong Buy.
• Despite the recent stock surge, Compass Therapeutics reported a quarterly loss of ($0.14) EPS, falling short of analysts' expectations.

Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX - Get Free Report) hit a new 52-week high during mid-day trading on Thursday . The stock traded as high as $4.09 and last traded at $4.07, with a volume of 1676156 shares trading hands. The stock had previously closed at $3.90.

Wall Street Analysts Forecast Growth

CMPX has been the subject of several research analyst reports. Weiss Ratings reissued a "sell (d-)" rating on shares of Compass Therapeutics in a report on Wednesday. Lifesci Capital assumed coverage on shares of Compass Therapeutics in a research note on Monday. They issued an "outperform" rating and a $10.00 target price for the company. Raymond James Financial raised shares of Compass Therapeutics to an "outperform" rating and set a $9.00 target price for the company in a research note on Tuesday, July 1st. D. Boral Capital reaffirmed a "buy" rating and issued a $32.00 target price on shares of Compass Therapeutics in a research note on Tuesday, August 12th. Finally, Guggenheim upped their target price on shares of Compass Therapeutics from $10.00 to $12.00 and gave the stock a "buy" rating in a research note on Tuesday, August 12th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $13.10.

Compass Therapeutics Trading Up 4.4%

The stock's 50 day moving average price is $3.33 and its 200 day moving average price is $2.63. The company has a market capitalization of $562.80 million, a price-to-earnings ratio of -9.04 and a beta of 1.48.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last posted its quarterly earnings data on Monday, August 11th. The company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.01). On average, research analysts expect that Compass Therapeutics, Inc. will post -0.36 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in CMPX. Creative Planning bought a new position in shares of Compass Therapeutics during the second quarter worth approximately $30,000. Strs Ohio bought a new position in shares of Compass Therapeutics during the first quarter worth approximately $34,000. Squarepoint Ops LLC bought a new position in shares of Compass Therapeutics during the fourth quarter worth approximately $35,000. Birchview Capital LP bought a new position in shares of Compass Therapeutics during the first quarter worth approximately $46,000. Finally, Walleye Trading LLC bought a new position in shares of Compass Therapeutics during the first quarter worth approximately $48,000. 68.43% of the stock is owned by institutional investors.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.